# Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab

Study · id `cardio:ct-nct04120753` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04120753](<https://clinicaltrials.gov/study/NCT04120753>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04120753

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

## Technical summary

Registry record NCT04120753. Randomized; no masking; primary purpose treatment. Start 2019-08-26 (actual); primary completion 2021-07-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 106 participants (enrolled count; ClinicalTrials.gov record NCT04120753, source copy `cardio:ctgov-nct04120753-2024-07-01`, retrieved 2026-10-26)
- Started: 2019-08-26 (actual) (ClinicalTrials.gov record NCT04120753, source copy `cardio:ctgov-nct04120753-2024-07-01`, retrieved 2026-10-26)
- Primary completion: 2021-07-06 (actual) (ClinicalTrials.gov record NCT04120753, source copy `cardio:ctgov-nct04120753-2024-07-01`, retrieved 2026-10-26)
- Completion: 2021-07-06 (actual) (ClinicalTrials.gov record NCT04120753, source copy `cardio:ctgov-nct04120753-2024-07-01`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04120753, source copy `cardio:ctgov-nct04120753-2024-07-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04120753-2024-07-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab
- Condition: Hypertension
- Condition: Dyslipidemias
- Intervention (Drug): OLOMAX 20/5/5mg
- Intervention (Drug): OLOMAX 20/5/10mg
- Intervention (Drug): Olmesartan 20 mg/Amlodipine 5 mg
- Lead sponsor: Daewoong Pharmaceutical Co. LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of a Single-Pill Triple Combination of Olmesartan, Amlodipine, and Rosuvastatin in Hypertensive Patients with Low-to-Moderate Cardiovascular Risk: A Multicenter, Randomized, Open-Label, Active-Control, Phase IV Clinical Trial (`cardio:pubmed-37814541`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 8667956ccfd4c235cb6095c9f26dd3a240f4e5a9673599d4d37a05a1a55f6deb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
